Comparative Pharmacology
Head-to-head clinical analysis: AEROSEB DEX versus HYTONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROSEB DEX versus HYTONE.
AEROSEB-DEX vs HYTONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The combination product contains a corticosteroid (dexamethasone) which suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and a topical antibiotic (usually neomycin or polymyxin B) which inhibits bacterial protein synthesis or disrupts bacterial cell membranes.
Hydrocortisone (topical) binds to glucocorticoid receptors, activating anti-inflammatory proteins and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
2 puffs (100 mcg each) intranasally twice daily
Topical: Apply cream or ointment to affected area 2-4 times daily. Limit treatment area to less than 50% of body surface area. Maximum duration: 2 weeks unless directed by physician.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
30–60 minutes (terminal elimination half-life; short duration requires frequent dosing)
Renal elimination of unchanged drug accounts for 30-40% of the dose; fecal/biliary elimination is 50-60% as metabolites. Less than 10% is excreted unchanged in feces.
Renal (primarily as metabolites; ~25% as unchanged drug) and biliary/fecal
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid